摘要
目的 :研究非小细胞肺癌中多药耐药相关蛋白 (MRP)的表达同临床病理特征和病人预后生存期的关系。方法 :采用免疫组织化学S P法检测 6 2例非小细胞肺癌中MRP的表达。结果 :6 2例非小细胞肺癌中MRP总阳性率为 83.88% (5 2 / 6 2 ) ,强阳性率为 4 6 .77% (2 9/ 6 2 ) ,其中鳞癌的阳性率为 87.5 0 % (35 / 4 0 ) ,腺癌为 77.2 7%(17/ 2 2 )。MRP表达与患者性别、组织分化程度、淋巴结转移均无关。MRP表达阴性者术后平均生存期为 (6 9.81± 17.4 1)月 ,表达阳性者为 (2 5 .38± 4 .4 6 )月 ,二者差异具有显著性 (P =0 .0 15 6 )。鳞癌中MRP阴性和阳性者术后生存期存在显著差异 (P =0 .0 15 3)。结论 :非小细胞肺癌中 ,尤其是鳞状细胞癌MRP的表达与术后生存期呈负相关 ,是影响病人预后的因素。MRP阴性表达者术后生存期相对较长。
Objective: This paper was to explore the relationships between expression of multidrug resistance associated protein (MRP) and clinicopathological parameters and prognosis. Methods: We detected the expression of MRP by using method of immunohistochemistry in 62 patients with non small cell lung cancer (NSCLC). Results: Our study of tumor tissue confirmed the plasma membrane or cytoplasm locations of the MRP. We found that the majority (83.88%) patients with NSCLC had detectable levels of MRP, and strong MRP expression was detected in 46.77% patients. But no potentially confounding correlation was observed between MRP expression and any clinicopathological parameters examined, including sex, histological type, tumor cell differentiation, lymphatic metastasis (P>0.05). The mean survival period of the patients with MRP negative expression was (69.81±17.41) months, and that of the patients with MRP positive expression was (25.38±4.46) months. Log rank test suggested that the difference between them was significant (P=0.0156). Furthermore, in squamous cell cancer we also found the statistically significant difference between the mean survival period of patients with MRP positive expression and those of patients with MRP negative expression (P=0.0153). Conclusion: High expression of MRP was predictive for worse survival, and it was a independent factor that affected prognosis. The mean survival period of patients with MRP negative expression was relative long.
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2002年第5期337-340,共4页
Journal of China Medical University
基金
教育部留学回国人员科研启动基金资助项目(2 0 0 2 2 47)
关键词
多药耐药相关蛋白
非小细胞肺癌
免疫组织化学
预后
multidrug resistance associated protein
non small cell lung cancer
immunohistochemistry
prognosis